Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $864.44 million. The enterprise value is $630.33 million.
| Market Cap | 864.44M |
| Enterprise Value | 630.33M |
Important Dates
The last earnings date was Tuesday, October 27, 2026, after market close.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 54.37 million shares outstanding. The number of shares has increased by 44.45% in one year.
| Current Share Class | 54.37M |
| Shares Outstanding | 54.37M |
| Shares Change (YoY) | +44.45% |
| Shares Change (QoQ) | +4.48% |
| Owned by Insiders (%) | 1.94% |
| Owned by Institutions (%) | 100.46% |
| Float | 42.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.79 |
| Forward PS | 5.54 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.92, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.92 |
| Quick Ratio | 8.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.88% and return on invested capital (ROIC) is -16.30%.
| Return on Equity (ROE) | -23.88% |
| Return on Assets (ROA) | -14.96% |
| Return on Invested Capital (ROIC) | -16.30% |
| Return on Capital Employed (ROCE) | -22.53% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $300,863 |
| Profits Per Employee | -$196,494 |
| Employee Count | 423 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.43 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.59% |
| 50-Day Moving Average | 19.04 |
| 200-Day Moving Average | 14.81 |
| Relative Strength Index (RSI) | 38.42 |
| Average Volume (20 Days) | 1,150,176 |
Short Selling Information
The latest short interest is 6.92 million, so 12.72% of the outstanding shares have been sold short.
| Short Interest | 6.92M |
| Short Previous Month | 6.05M |
| Short % of Shares Out | 12.72% |
| Short % of Float | 16.41% |
| Short Ratio (days to cover) | 4.82 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $127.27 million and -$83.12 million in losses. Loss per share was -$1.85.
| Revenue | 127.27M |
| Gross Profit | 74.61M |
| Operating Income | -92.58M |
| Pretax Income | -83.12M |
| Net Income | -83.12M |
| EBITDA | -89.86M |
| EBIT | -92.58M |
| Loss Per Share | -$1.85 |
Balance Sheet
The company has $240.20 million in cash and $6.10 million in debt, with a net cash position of $234.10 million or $4.31 per share.
| Cash & Cash Equivalents | 240.20M |
| Total Debt | 6.10M |
| Net Cash | 234.10M |
| Net Cash Per Share | $4.31 |
| Equity (Book Value) | 401.38M |
| Book Value Per Share | 7.38 |
| Working Capital | 260.11M |
Cash Flow
In the last 12 months, operating cash flow was -$59.37 million and capital expenditures -$6.59 million, giving a free cash flow of -$65.96 million.
| Operating Cash Flow | -59.37M |
| Capital Expenditures | -6.59M |
| Depreciation & Amortization | 2.72M |
| Net Borrowing | n/a |
| Free Cash Flow | -65.96M |
| FCF Per Share | -$1.21 |
Margins
Gross margin is 58.63%, with operating and profit margins of -72.75% and -65.31%.
| Gross Margin | 58.63% |
| Operating Margin | -72.75% |
| Pretax Margin | -65.31% |
| Profit Margin | -65.31% |
| EBITDA Margin | -70.61% |
| EBIT Margin | -72.75% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -44.45% |
| Shareholder Yield | -44.45% |
| Earnings Yield | -11.62% |
| FCF Yield | -7.63% |
Analyst Forecast
The average price target for Beta Bionics is $25.10, which is 57.86% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.10 |
| Price Target Difference | 57.86% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 42.04% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of 10.25 and a Piotroski F-Score of 2.
| Altman Z-Score | 10.25 |
| Piotroski F-Score | 2 |